文献速递乳腺癌

融合超声影像组学与临床病理特征的可解释AI预测新辅助治疗后HER2变化:多中心研究

Prediction of HER2 changes post-neoadjuvant therapy based on fusion of ultrasound radiomics and clinicopathological features empowered by explainable AI: A multicenter study.
PubMed 文献 · Eur J Cancer · 2025-11-29

该多中心回顾性研究纳入655例有配对新辅助治疗前后HER2评估的乳腺癌患者,构建融合治疗前超声影像组学与临床病理参数的可解释UICFF框架预测HER2状态演变。模型内部和外部AUC分别为0.811和0.823,优于单模态模型;动态HER2变化与HER2阻断病理反应改善相关,但对5年无事件生存无独立影响。

要点

  • UICFF多模态模型可无创预测新辅助治疗后HER2状态变化,外部AUC为0.823。
  • 动态HER2变化与HER2阻断病理反应改善相关(58.6% vs 38.1%)。
  • 动态HER2变化对5年无事件生存无独立影响。

核心结论

  • 可解释UICFF框架可在治疗前个体化预测新辅助治疗患者的HER2演变,为重复活检提供无创替代。

研究设计与样本

  • 多中心回顾性研究,2017年1月至2023年5月从三家机构纳入655例有配对治疗前后HER2评估的乳腺癌患者。
  • 提取治疗前超声影像组学特征并结合基线HER2状态、新辅助治疗方案等临床病理参数,构建注意力引导多模态特征选择的UICFF框架。
  • 模型性能与六种经典基线及两种单模态基线比较,生存结局采用Kaplan-Meier分析。

主要发现

  • 训练、内部和外部队列中动态HER2改变发生率分别为29.7%、34.6%和25.5%。
  • UICFF内部AUC为0.811、外部AUC为0.823,外部较影像组学单模态和临床病理单模态ΔAUC分别为+0.193和+0.125。
  • SHAP分析显示年龄、绝经状态、Ki-67指数和小波纹理特征为主要预测因子,年轻和较大肿瘤与HER2动态变化正相关。
  • 动态HER2变化与HER2阻断病理反应改善相关(58.6% vs 38.1%),但对5年无事件生存无独立影响。

临床怎么用

  • 治疗前可利用超声影像组学联合临床病理参数无创预测新辅助治疗后HER2状态演变。
  • 模型可解释性有助于识别年龄、绝经状态、Ki-67指数等关键预测因素。
  • 动态HER2变化与HER2阻断病理反应改善相关,可辅助治疗决策参考。

局限性

  • 为多中心回顾性研究,需前瞻性验证。
  • 动态HER2变化对5年无事件生存无独立影响,长期获益尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dynamic HER2 expression changes during neoadjuvant therapy (NAT) challenge precision oncology. Current biopsy-dependent evaluation inadequately meets clinical needs for dynamic monitoring. We developed a non-invasive predictive model integrating pretreatment ultrasound radiomics and clinicopathological parameters to forecast post-NAT HER2 status evolution in breast cancer. METHODS: In this multicenter retrospective study (January 2017-May 2023), 655 patients with paired pre- and post-NAT HER2 assessments were enrolled from three institutions. Pretreatment ultrasound images underwent manual tumor segmentation and radiomic feature extraction. Clinicopathological parameters, including baseline HER2 status and NAT regimen, were retrospectively collected. An Ultrasound Image Clinical Feature Fusion (UICFF) framework incorporating attention-guided multimodal feature selection was developed for HER2 transition prediction. Model performance was compared with six classical and two unimodal baselines. Survival outcomes were evaluated using Kaplan-Meier analysis. RESULTS: Dynamic HER2 alterations occurred in 29.7 %, 34.6 %, and 25.5 % of the training, internal, and external cohorts, respectively. The multimodal UICFF achieved superior discrimination (AUC_internal = 0.811; AUC_external = 0.823), outperforming radiomics-only and clinicopathological-only models (external ΔAUCs: +0.193 and +0.125, respectively). SHapley Additive exPlanations analysis identified age, menopausal status, Ki-67 index, and wavelet-based texture features as dominant predictors. Younger age and larger tumor size were positively associated with HER2 dynamics. Dynamic HER2 changes correlated with improved pathological response to HER2 blockade (58.6 % vs. 38.1 %) but showed no independent effect on 5-year event-free survival. CONCLUSIONS: The interpretable UICFF framework enables individualized, pretreatment prediction of HER2 evolution in patients undergoing NAT, providing a clinically actionable and noninvasive alternative to repeated biopsies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yan Y, Xue X, Xie J, et al. Prediction of HER2 changes post-neoadjuvant therapy based on fusion of ultrasound radiomics and clinicopathological features empowered by explainable AI: A multicenter study. Eur J Cancer. 2025. PMID: 41352003. doi:10.1016/j.ejca.2025.116158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。